Exhibit (a)(5)(C)


Excerpt from the Transcript of Danaher's First Quarter 2006 Earnings Call on
April 20, 2006


MANAGEMENT DISCUSSION SECTION

[MATERIAL NOT RELEVANT]

Last week, we announced our tender offer for Sybron Dental Specialties. Sybron
based in Newport Beach, California is a leading manufacturer of dental
consumables and small equipment. Sybron's revenues for the fiscal year ended
September 30th, 2005, were approximately $650 million. This offer is subject to
customary conditions, including the tender of a majority of the outstanding
shares into the offer, regulatory approvals and the absence of a material
adverse change with respect to Sybron Dental. We expect to fund the purchase
price through the combination of available cash and debt and expect to complete
the transaction in the second quarter of 2006. We believe the acquisition of
Sybron Dental would represent an excellent addition to our existing dental
products portfolio and we look forward to working with the talented team at
Sybron.


[MATERIAL NOT RELEVANT]





QUESTION AND ANSWER SECTION

Operator: At this time, I would like to remind everyone in order to ask a
question, press star then the number one on your telephone keypad. We will pause
for just a moment to compile the Q&A roster.

[MATERIAL NOT RELEVANT]

Q- Bob Cornell: KaVo, Larry.

A - Larry Culp: KaVo, obviously if we weren't feeling great about our dental
business, Bob, we wouldn't be talking about putting two plus billion dollars on
the table for Sybron. We saw, as we indicated in our prepared remarks, positive
impact, positive results from the restructuring activities, but more
importantly, the new products the sales force changes the go to market programs,
we are very pleased with what we're seeing. I think when you see the imaging
sales up at the way they are, I think, you're seeing tangible evidence of how
DBS can have impact not only in product development, but also on our go to
market activities in the Dental space. And as we look to Sybron, a company we
think will be an excellent addition, we just see more opportunity to do just
that. Obviously a different context, because Sybron is more successful
historically than KaVo, but in both instances we see a lot of run way, a lot of
opportunity.

[MATERIAL NOT RELEVANT]

Q - John Inch: Maybe just a final one on Sybron. I see it's trading above your
offer price. If I remember, Dan, on the 12th, you made the comment that to get
to your ROI, you have to look out five years. I mean if someone does counter,
can I interpret or can we interpret those comments to suggest that it would be
unlikely that you would counter that just based on the ROI dynamic?

A - Larry Culp: John, can I jump in there?

Q - John Inch: Sure.

A - Larry Culp: I think it is - what we read here in the last day or so actually
gave us great encouragement. We know this is an excellent company, as we
indicated last week. We think it's a great addition to Danaher. We like the
product balance here, equipment consumables, we like the geographic balance
given where they are here in the US. We like the joint opportunities,
short-term, long-term between the businesses. As you indicated, like Fluke, like
Hach while we're paying perhaps a full price here, we think this is a value
creator for our shareholders. The documentation that they filed clearly I think
encourages us. There are no other firm offers out there. The other parties that
were in the hunt, if I can use that term, clearly admitted they have more work
to do and they have significant regulatory hurdles. So you put all that
together, I think we - we clearly think this is going to be a winner for us. And
if I can add, I was out there Monday. The first opportunity, I've been able to
have with the team since we made the announcement, I was very encouraged by the
reaction that we received. The team is very pumped up and am talking not only
about the senior team but the broader management group, a quality group of
people. All of them have their own list of ideas, of things that we can do
together. The public response and I'm speaking not really to the market,
but those in the industry, has been very positive really without exception. So,
we're excited about



doubling the size of our dental business. We're excited about what this does for
our Medtech platform and obviously would position Danaher at a very close to $10
billion revenue level. So all up obviously, this is a big move for us, but one
that we're excited and confident about.

Q - John Inch: And then - can you just remind us what is the hard date, the 30
day tender whenever then when if you - presuming you guys get the deal, when is
it expected to close again?

A - Larry Culp: I believe its May 15 or May 16.

Q - John Inch: And then it closes then --?

A - Larry Culp: We wouldn't - I mean assuming we have more than 50%, we would
take that down and have control of the company. We think we got all our
regulatory filings done in the next day or two we would expect to take down
control of the company within the next four weeks.

[MATERIAL NOT RELEVANT]

Q - Ann Duignan: I think I'm just going to change my name. Just following up on
John's question there, assuming that the deal does go through, your 10-Q states
that management and other personnel would be required to devote significant
attention to the successful integration of the business. Larry, should I read
anymore into that than just the standard statement or does this imply somewhat
that once you get this acquisition that the pace of acquisitions may have to
slow for a while?

A - Larry Culp: Ann, I think your first take is spot on. Obviously, there are
requirements in those filings that some of our attorneys help us with, but
without in anyway understating the magnitude of the investment that we're making
at Sybron, it's really - we're inheriting, we think a very competent team out
there, a team that we are excited to have as part of Danaher and based on what I
saw on Monday, a team that will be part of what we're about. We think that we
actually have limited impact elsewhere. It doesn't really pull on our electronic
test team, our product I.D. team, I can go right down the line, and while it's
our largest transaction, we don't think it puts us out in deal game this year.
So, we would still expect, as I tried to indicate last week, that we will be
active this year, elsewhere, outside of Sybron in making investments that we
think create long-term value and competitive advantage for Danaher.

Q - Ann Duignan: Okay. And following along the same lines, do you see any out
the changes in your organizational structure coming about now that you've built
out the scale in some of these new business segments? For example, would you
consider an office of COO or some structure like that, or are you comfortable
with the way that these businesses are kind of expanding the control as they
stand today?

A - Larry Culp: Well, Ann, that's an excellent question, because it's something
that we always are thinking about, given the growth, growth always demands, I
think, adjustments in the org structure. But we have had in the five years that
I've been CEO, what we call our Office of the Chief Executive, which is really
the senior team, Pat and Dan, Phil Knisely, Steve Simms. We added Jim Lico to
that group last year, I think not only in recognition of his tremendous
performance, but also



the growth that we've had and the growth that we anticipate. So, as we look at
that OCE, as we call it, we look at the leadership team broadly, we feel good
about our capital and our bandwidth in that regard. But obviously as the
organization evolves, we'll make adjustments as appropriate. But again, I think
in the case of Sybron, they were in the process of a[n] organizational
transition themselves, a CEO succession, Dan Even their [COO] steps up here and
we're excited about having him take the reins of that business with us.

[MATERIAL NOT RELEVANT]